Phase 2 Endometrial Cancer Trial, Recruiting NCT05979610 Sponsor: University of Utah Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT05979610
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with a confirmed cancer of the uterus lining (endometrium), cervix, vagina, or vulva
  • People whose treatment plan includes a type of internal radiation therapy called brachytherapy, given as an outpatient (meaning no overnight hospital stay is required)
  • People who can read and understand English and/or Spanish
  • People who are able to understand the study information and are willing to sign a consent form agreeing to take part
  • People who are willing to be assigned to either the Reiki therapy group or the standard care group, whichever the trial places them in

Who may not be able to join:

  • People who have previously received brachytherapy (internal radiation) for a gynaecological cancer
  • People with medical, psychiatric, cognitive, or other conditions that may make it difficult to understand the study information, give consent, or follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lindsay Burt, MD, Huntsman Cancer Institute/ University of Utah

Phone: 801-587-4713

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
14 November 2023
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Comparison between the treatment groups of the change in anxiety from Assessment 1 to Assessment 3 as measured by the 6-item Spielberger State Anxiety Scale.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov